Cetilistat, a new lipase inhibitor for the treatment of obesity.
Alizyme plc, in collaboration with Takeda Pharmaceutical Co Ltd in Japan, is developing cetilistat, an oral non-absorbed synthetic lipase inhibitor, derived from Alizyme's pancreatic lipase inhibitor research program, for the potential treatment of obesity in patients with or without diabetes. It is also under investigation for the potential management of type 2 diabetes. Several phase II clinical trials for obesity have been completed. Phase III trials were in preparation at the time of publication.